LeMaitre Vascular (NASDAQ:LMAT) Updates Q2 2026 Earnings Guidance

Key Points

• LeMaitre updated Q2 2026 guidance to EPS $0.790–$0.840 (consensus $0.760) and revenue guidance of $70.5M–$72.5M (consensus $71.5M), and set FY 2026 EPS guidance at $2.930–$3.080.
• Several analyst upgrades left the stock with an average rating of Moderate Buy and an average price target of $105.80, including Roth MKM raising its target to $117.
• The company raised its quarterly dividend to $0.25 ($1.00 annualized, ~0.9% yield), while insiders sold about 215,438 shares (~$23.1M) in the past three months; insiders now own 7.4% of the stock.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its second quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.790-0.840 for the period, compared to the consensus earnings per share estimate of 0.760. The company issued revenue guidance of $70.5 million-$72.5 million, compared to the consensus revenue estimate of $71.5 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.930-3.080 EPS.

Analysts Set New Price Targets

A number of analysts have commented on the company. Roth Mkm restated a "buy" rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Weiss Ratings raised LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, March 10th. Zacks Research upgraded LeMaitre Vascular from a "hold" rating to a "strong-buy" rating in a research note on Monday, April 13th. Freedom Capital raised shares of LeMaitre Vascular to a "hold" rating in a report on Tuesday, March 31st. Finally, Wall Street Zen raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $105.80.

LeMaitre Vascular Price Performance

NASDAQ:LMAT traded up $0.79 on Tuesday, reaching $112.32. 225,458 shares of the company's stock traded hands, compared to its average volume of 204,146. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $108.90 and a 200-day simple moving average of $93.99. The firm has a market cap of $2.57 billion, a PE ratio of 44.75, a P/E/G ratio of 3.23 and a beta of 0.60. LeMaitre Vascular has a 12 month low of $78.35 and a 12 month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts forecast that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, March 12th. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.20. LeMaitre Vascular's dividend payout ratio is currently 39.84%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company's stock, valued at $1,920,157.20. This trade represents a 32.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 55,930 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the sale, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. The trade was a 3.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 215,438 shares of company stock valued at $23,062,911 in the last three months. 7.40% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently bought and sold shares of the stock. Illinois Municipal Retirement Fund boosted its holdings in shares of LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier's stock valued at $906,000 after purchasing an additional 123 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier's stock worth $256,000 after purchasing an additional 139 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier's stock worth $3,294,000 after buying an additional 155 shares in the last quarter. Equitable Holdings Inc. boosted its stake in LeMaitre Vascular by 1.4% during the fourth quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier's stock valued at $1,173,000 after buying an additional 205 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in LeMaitre Vascular by 1.7% during the second quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier's stock valued at $1,555,000 after buying an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.